Alpha 2.0
Login Register
» Authors » Yuji Iizawa

Yuji Iizawa

Explore the profile of Yuji Iizawa including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 19
Citations 596
Followers 0
Related Specialties
Pharmacology
Chemistry
Biochemistry
Top 10 Co-Authors
Masanori Baba
Naoyuki Kanzaki
Shohei Hashiguchi
Yoshihiro Sugihara
Katsunori Takashima
Mitsuru Shiraishi
Tomoyuki Kitazaki
Masaki Seto
Yoshio Aramaki
Masayuki Ii
Published In
Antimicrob Agents Chemother
Bioorg Med Chem
Chem Pharm Bull (Tokyo)
J Med Chem
Eur J Pharmacol
Affiliations
Soon will be listed here.
Recent Articles
1.
Combination of imipenem and TAK-242, a Toll-like receptor 4 signal transduction inhibitor, improves survival in a murine model of polymicrobial sepsis
Sha T, Iizawa Y, Ii M
Shock . 2010 Aug; 35(2):205-9. PMID: 20720515
Sepsis is characterized by an excessive host response to infection. Toll-like receptors (TLRs) are essential for triggering this type of host immune response. Toll-like receptor 4 mediates recognition of LPS...
2.
TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain
Kawamoto T, Ii M, Kitazaki T, Iizawa Y, Kimura H
Eur J Pharmacol . 2008 Feb; 584(1):40-8. PMID: 18299127
TAK-242, a small-molecule antisepsis agent, has shown to suppress lipopolysaccharide (LPS)-induced inflammation. In this study, we demonstrate that TAK-242 is a selective inhibitor of Toll-like receptor (TLR)-4 signaling. TAK-242 almost...
3.
Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model
Sha T, Sunamoto M, Kitazaki T, Sato J, Ii M, Iizawa Y
Eur J Pharmacol . 2007 Jul; 571(2-3):231-9. PMID: 17632100
Ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), a novel small molecule that selectively inhibits Toll-like receptor 4-mediated signaling, inhibits various kinds of inflammatory mediators such as nitric oxide (NO), tumor necrosis factor (TNF)-alpha, interleukin...
4.
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity
Imamura S, Ichikawa T, Nishikawa Y, Kanzaki N, Takashima K, Niwa S, et al.
J Med Chem . 2006 Apr; 49(9):2784-93. PMID: 16640339
We incorporated various polar groups into previously described piperidine-4-carboxamide CCR5 antagonists to improve their metabolic stability in human hepatic microsomes. Introducing a carbamoyl group into the phenyl ring of the...
5.
Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety
Seto M, Aikawa K, Miyamoto N, Aramaki Y, Kanzaki N, Takashima K, et al.
J Med Chem . 2006 Mar; 49(6):2037-48. PMID: 16539392
Chemical modification has been performed on an orally bioavailable and potent CCR5 antagonist, sulfoxide compound 4, mainly focusing on replacement of the [6,7]-fused 1-benzazepine nucleus. We designed, synthesized, and evaluated...
6.
A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling
Ii M, Matsunaga N, Hazeki K, Nakamura K, Takashima K, Seya T, et al.
Mol Pharmacol . 2005 Dec; 69(4):1288-95. PMID: 16373689
Proinflammatory mediators such as cytokines and NO play pivotal roles in various inflammatory diseases. To combat inflammatory diseases successfully, regulation of proinflammatory mediator production would be a critical process. In...
7.
TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans
Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, et al.
Antimicrob Agents Chemother . 2005 Oct; 49(11):4584-91. PMID: 16251299
The first small-molecule CCR5 antagonist, TAK-779, could not be developed as an anti-human immunodeficiency virus type (anti-HIV-1) agent because of its poor oral bioavailability. TAK-652 is an orally bioavailable TAK-779...
8.
Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist
Takashima K, Miyake H, Kanzaki N, Tagawa Y, Wang X, Sugihara Y, et al.
Antimicrob Agents Chemother . 2005 Jul; 49(8):3474-82. PMID: 16048963
TAK-220 is a member of a novel class of chemokine receptor antagonists and is highly specific to CCR5, as determined by receptor binding and calcium mobilization assays. The compound selectively...
9.
CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives
Imamura S, Nishikawa Y, Ichikawa T, Hattori T, Matsushita Y, Hashiguchi S, et al.
Bioorg Med Chem . 2004 Dec; 13(2):397-416. PMID: 15598561
Replacement of the 5-oxopyrrolidin-3-yl fragment in the previously reported lead structure with a 1-acetylpiperidin-4-yl group led to the discovery of a novel series of potent CCR5 antagonists. Introduction of small...
10.
Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety
Seto M, Miyamoto N, Aikawa K, Aramaki Y, Kanzaki N, Iizawa Y, et al.
Bioorg Med Chem . 2004 Dec; 13(2):363-86. PMID: 15598559
In order to develop orally active CCR5 antagonists, 1-propyl- or 1-isobutyl-1-benzazepine derivatives containing a sulfoxide moiety have been designed, synthesized, and evaluated for their biological activities. Sulfoxide compounds containing a...